RhumbLine Advisers’s Radiopharm Theranostics RADX Stock Holding History

RhumbLine Advisers’s Portfolio RADX Stock Details RADX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$817	Buy	195 +74	+61%	+$329	﹤0.01%	4037
2026 Q1	$519	Buy	121 +115	+1,917%	+$562	﹤0.01%	4010
2025 Q4	$31	Buy	+6	New	+$32	﹤0.01%	4113

Other funds holding RADX

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Regal Partners Sydney, NSW, Australia $1.81B AUM 52.11% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers's RADX Position: Q2 2026 in Review

RhumbLine Advisers increased its Radiopharm Theranostics (RADX) stake by 61% in Q2 2026, buying an estimated $329 and bringing the position to 195 shares worth $817. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

RhumbLine Advisers first reported a position in RADX in Q4 2025 and has held it in 3 quarters since. 6 funds tracked by Wall St. Rank hold RADX as of Q2 2026.

RhumbLine Advisers held 195 shares of Radiopharm Theranostics worth $817 as of Q2 2026.
RhumbLine Advisers bought 74 Radiopharm Theranostics shares in Q2 2026, an estimated $329.
Radiopharm Theranostics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #4037 holding.
RhumbLine Advisers first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 3 quarters since.
6 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.